Bevacizumab-tnjn - Biologic Drug Details

Summary for bevacizumab-tnjn

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for bevacizumab-tnjn

Mechanism of Action	Vascular Endothelial Growth Factor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions
Established Pharmacologic Class	Vascular Endothelial Growth Factor Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab-tnjn Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for bevacizumab-tnjn Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for bevacizumab-tnjn Derived from Patent Text Search

No patents found based on company disclosures

Bevaczizumab-tnjn Market Dynamics and Financial Trajectory

Last updated: February 27, 2026

What is Bevaczizumab-tnjn?

Bevacizumab-tnjn is an off-label biosimilar of the original biologic drug bevacizumab (brand name Avastin). It is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), a key driver of angiogenesis. The drug is primarily used for cancer treatment. Its regulatory status varies across regions, often used off-label due to patent expirations of the reference product.

Patent and Regulatory Landscape

• Patent Expiry of Reference Product: Original bevacizumab patents expired in 2018 in the US and Europe, paving the way for biosimilar entry.
• Biosimilar Approvals: Several biosimilars entered the market post-2018, with bevacizumab-tnjn gaining approvals in select markets based on regulatory pathways like the FDA’s 351(k) biosimilar pathway or the EMA’s biosimilar guidelines.
• Off-Label Use: Some regions permit off-label use of biosimilars like bevacizumab-tnjn for indications approved for the reference biologic, impacting sales volumes.

Market Size and Growth Drivers

Metric	Value	Source/Notes
Global oncology biologics market (2022)	$150 billion	[1]
Estimated bevacizumab sales (2022)	$7 billion	[2]
Biosimilar market penetration (2022)	18%	[3]

• Market Expansion: The global oncologic biologic market grows at a 7% annual rate. Biosimilars, including bevacizumab-tnjn, share increasing market share, driven by patent cliffs and cost pressures.
• Cost Savings: Biosimilars reduce treatment costs by 20-30%, incentivizing formulary inclusion and off-label use.
• Pricing Pressure: Entry of biosimilars has resulted in a 15-25% decrease in reference product prices, which affects revenue streams for both originators and biosimilar manufacturers.

Competitive Landscape

Competitors	Market Share (2022)	Notable Biosimilar Products
Roche	42%	Avastin (original)
Pfizer	25%	Zirabev, Mvasi
Amgen	15%	Amgevita (for related biologics)
Others	18%	Various biosimilars including bevacizumab-tnjn

• Market Entry: Multiple biosimilars for bevacizumab are approved in the US, Europe, and emerging markets, increasing competition.
• Pricing Strategies: Biosimilar manufacturers often price their products 20-30% below the reference biologic to gain market share.

Financial Trajectory Projections

Revenue Estimates (2023-2027)

Year	Estimated Global Revenue	Growth Rate	Comments
2023	$500 million	-	Early market adoption in select regions
2024	$1 billion	100%	Rising off-label use; expanding access
2025	$1.4 billion	40%	Increased formulary positioning
2026	$1.8 billion	28.6%	Entry into additional markets
2027	$2.2 billion	22.2%	Stabilization phase

Key Factors Influencing Revenue

• Regulatory Approvals: Rapid approval in key markets accelerates revenue growth.
• Market Penetration: Off-label use and hospital formulary acceptance dominate sales channels.
• Pricing Trends: Erosion of biosimilar prices by 10-15% annually may impact margins.
• Reimbursement Policies: Favorable coverage can elevate utilization rates; restrictive policies hinder growth.

Challenges to Financial Growth

• Limited IP Exclusivity: Patent expirations lead to increased biosimilar competition.
• Market Saturation: Most major markets have multiple biosimilars, reducing potential pricing power.
• Clinical Acceptance: Physicians may prefer reference biologics or other biosimilars with longer market presence.
• Regulatory Variability: Lack of uniform approval standards across regions delays global expansion.

Opportunities for Growth

• Indication Expansion: Potential approvals for additional indications such as age-related macular degeneration can bolster revenue.
• Market Penetration Strategy: Targeting emerging markets where biologic adoption is increasing.
• Cost Leadership: Competitive pricing can increase volume sales, particularly in value-sensitive healthcare systems.
• Partnerships: Collaborations with health systems to promote off-label use.

Key Takeaways

• Bevaczizumab-tnjn operates within a rapidly expanding biosimilar segment of the oncology biologics market.
• Market growth is driven by patent expirations, cost pressures, and increasing biosimilar acceptance.
• Revenue potential depends on regulatory approval speed, market penetration, and pricing strategies.
• The competitive landscape is intensifying, with traditional biologics and biosimilars vying for market share.
• Financial trajectory projections indicate significant growth potential, tempered by pricing erosion and regulatory challenges.

FAQs

1. How does bevacizumab-tnjn compare in price to the original bevacizumab?
Biosimilars like bevacizumab-tnjn typically cost 20-30% less than the reference biologic, depending on the market and negotiation power.

2. What are the primary risks affecting its market growth?
Regulatory delays, market saturation, physician resistance, and reimbursement policies can hinder growth.

3. Which regions are most favorable for bevacizumab-tnjn’s expansion?
Emerging markets with expanding healthcare coverage, such as Latin America, Asia-Pacific, and Eastern Europe, present growth opportunities.

4. How does off-label use influence sales?
Off-label use significantly increases utilization, especially where regulatory restrictions are less stringent, offsetting some declines in reference product sales.

5. What are the key factors that could accelerate revenue growth?
Faster regulatory approvals, indication expansions, and strategic partnerships focusing on emerging markets will likely boost revenue.

---

References

1. MarketWatch. (2022). Oncology biologics market size and forecast.
2. EvaluatePharma. (2022). Global biologics sales data.
3. IQVIA. (2022). Biosimilar market penetration reports.